Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 25.2% from a year ago
Cash & equivalents stood at $26.95M at the end of Q3 FY2026, down 25.2% from a year earlier and down 43.2% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Cash & equivalents amounted to 3.7% of total assets at the end of Q3 FY2026, down 1.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -25.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 28.87M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- -7.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.87M | +1.8% |
| FY2024 | 2024-12-31 | 28.36M | -18.6% |
| FY2023 | 2023-12-31 | 34.81M | +18.3% |
| FY2022 | 2022-12-31 | 29.43M | -24.8% |
| FY2021 | 2021-12-31 | 39.14M | — |
Cash & Equivalents vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's Sep 2026 cash & equivalents of $26.95M is the 9th highest of the 10 companies compared; the peer median is $66.52M.
- Its year-over-year change of -25.2% is the 8th highest of 10, against a peer median of -12.5%.
- Cash & equivalents amounts to 3.7% of total assets for CLDX, versus a peer median of 26.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Sep 2026 | $212.84M | -21.9% | +218.0% | 42.1% | |
| Jun 2026 | $150M | -39.5% | +2.5% | 16.2% | |
| Dec 2025 | $74.52M | -12.5% | -19.7% | 95.2% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $55.17M | +34.4% | -4.3% | 26.9% | |
| Jun 2026 | $44.66M | +0.5% | +0.1% | 6.2% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Sep 2026 | $26.95M | -25.2% | -0.6% | 3.7% | |
| Mar 2026 | $12.44M | -14.7% | +101.6% | 8.5% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $66.52M | -12.5% | +0.1% | 26.9% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 39.14M | 29.43M | 34.81M | 28.36M | 28.87M |
| Short-term Investments | 369.11M | 275.52M | 386.88M | 696.93M | 489.7M |
| Net Receivables | 172K | 347K | 4.53M | 700K | 2.02M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 5.47M | 21.18M | 14.08M |
| Total Current Assets | 410.84M | 317.69M | 431.69M | 747.16M | 534.66M |
| Property, Plant & Equipment (Net) | 6.52M | 7.75M | 6.64M | 8.24M | 7.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 104K | 104K | 107K | 9.75M | 13.36M |
| Total Non-current Assets | 33.82M | 35.04M | 33.93M | 45.18M | 48.32M |
| Total Assets | 444.65M | 352.74M | 465.63M | 792.34M | 582.98M |
| Account Payables | 1.23M | 3.34M | 3.49M | 3.27M | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.55M | 990K | 3.99M | 942K | 1.23M |
| Total Current Liabilities | 16.53M | 18.61M | 31.13M | 39.5M | 50.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.35M | 5.33M | 4.4M | 3.47M | 4.04M |
| Total Non-current Liabilities | 8.65M | 7.92M | 5.33M | 5.83M | 4.83M |
| Total Liabilities | 25.18M | 26.53M | 36.46M | 45.34M | 55.82M |
| Common Stock | 47K | 47K | 56K | 66K | 67K |
| Retained Earnings | (1.14B) | (1.26B) | (1.4B) | (1.56B) | (1.81B) |
| Accumulated OCI | 1.89M | 1.26M | 3.31M | 3.31M | 3.63M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 419.48M | 326.2M | 429.17M | 747.01M | 527.17M |
| Total Debt | 3.04M | 4.03M | 2.54M | 3.81M | 2.34M |
| Net Debt | (36.1M) | (25.4M) | (32.27M) | (24.54M) | (26.54M) |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.